310 related articles for article (PubMed ID: 18316624)
1. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
Sini P; Samarzija I; Baffert F; Littlewood-Evans A; Schnell C; Theuer A; Christian S; Boos A; Hess-Stumpp H; Foekens JA; Setyono-Han B; Wood J; Hynes NE
Cancer Res; 2008 Mar; 68(5):1581-92. PubMed ID: 18316624
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
[TBL] [Abstract][Full Text] [Related]
3. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
Hess-Stumpp H; Haberey M; Thierauch KH
Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
[TBL] [Abstract][Full Text] [Related]
4. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity.
Yamamoto A; Watanabe H; Sueki H; Nakanishi T; Yasuhara H; Iijima M
J Dermatol; 2007 Jul; 34(7):419-29. PubMed ID: 17584317
[TBL] [Abstract][Full Text] [Related]
8. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells.
Lacal PM; Ruffini F; Pagani E; D'Atri S
Int J Oncol; 2005 Dec; 27(6):1625-32. PubMed ID: 16273219
[TBL] [Abstract][Full Text] [Related]
9. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
Camp ER; Yang A; Liu W; Fan F; Somcio R; Hicklin DJ; Ellis LM
Clin Cancer Res; 2006 Apr; 12(8):2628-33. PubMed ID: 16638876
[TBL] [Abstract][Full Text] [Related]
10. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.
Zeng Y; Opeskin K; Goad J; Williams ED
Cancer Res; 2006 Oct; 66(19):9566-75. PubMed ID: 17018613
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.
Hos D; Bock F; Dietrich T; Onderka J; Kruse FE; Thierauch KH; Cursiefen C
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1836-42. PubMed ID: 18436817
[TBL] [Abstract][Full Text] [Related]
12. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
[TBL] [Abstract][Full Text] [Related]
13. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.
Weigand M; Hantel P; Kreienberg R; Waltenberger J
Angiogenesis; 2005; 8(3):197-204. PubMed ID: 16328160
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines.
Fukasawa M; Korc M
Clin Cancer Res; 2004 May; 10(10):3327-32. PubMed ID: 15161686
[TBL] [Abstract][Full Text] [Related]
17. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
19. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition.
Zips D; Eicheler W; Geyer P; Hessel F; Dörfler A; Thames HD; Haberey M; Baumann M
Cancer Res; 2005 Jun; 65(12):5374-9. PubMed ID: 15958586
[TBL] [Abstract][Full Text] [Related]
20. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
Shin VY; Wu WK; Chu KM; Wong HP; Lam EK; Tai EK; Koo MW; Cho CH
Mol Cancer Res; 2005 Nov; 3(11):607-15. PubMed ID: 16317086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
